Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma

NCT ID: NCT01450215

Last Updated: 2016-03-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 62 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-03-31

Brief Summary

This is:

• A prospective, randomized, open, phase II, multi-centre, interventional study. Patients who are in at least PR and have received lenalidomide as 2nd line treatment for MM will be recruited.
• The patients will be randomized into two groups. Group R will receive lenalidomide 25 mg/day p.o. continuously for 21 days and group Rb will receive a similar dose of lenalidomide with the addition of 40 mg of dexamethasone p.o. on days 1, 8, 15 and 22 of every 28 day treatment cycle. Study includes a maximum of 24 cycles including two consolidating cycles per patients.

Conditions

Multiple Myeloma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Revlimid

Group Type: EXPERIMENTAL

Revlimid

Intervention Type: DRUG

Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .

Revlimid and dexamethasone

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Revlimid

Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Be at least 18 years of age

2. Subjects must have a documented diagnosis of MM and have either refractory or relapsed and refractory after first line treatment disease defined as:

• Primary refractory
• Refractory
• Relapsed and Refractory

3. Subjects must have undergone prior treatment with one treatment line of anti-myeloma therapy. Induction therapy followed by ASCT and consolidation/maintenance will be considered as one line.Have a confirmed diagnosis of MM

4. Have received lenalidomide after one prior treatment for MM and have reached at least a partial response (PR), according to IMWG criteria, including two consolidating cycles. Subjects have experienced a response at least PR after starting treatment with lenalidomide and cortisone cycles.

5. Have personally signed and dated a legally effective written informed consent form prior to admission to the study.

6. Must be willing and able to understand and comply with the study requirements.

7. Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception.

8. Male must agree to practice contraception

Exclusion Criteria

1. Any of the following laboratory abnormalities:

• Absolute neutrophil count (ANC) < 1,000/µL
• Platelet count < 75,000/ µL
• Creatinine Clearance < 45 mL/min according to Cockcroft-Gault formula
• Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)
• Serum total bilirubin > 2.0 mg/dL

2. ECOG performance status <4.

3. Individuals who have had a stem-cell transplant as a 2nd line treatment for MM

4. Individuals who have taken any experimental drugs or participated in a clinical trial within 30 days prior to screening.

5. Individuals with significant psychiatric illness or a clinically significant acute/chronic uncontrolled medical condition that might affect their experience of myeloma symptoms or their ability to describe them.

6. Pregnant or lactating females.

7. Any other clinically significant medical disease or condition that, in the Investigator´s opinion, may interfere with protocol adherence or a subject´s ability to give informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Karolinska University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Hareth Nahi

MD, PhD, clinical assoc.professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Karolinska Inst.

Stockholm, , Sweden

Karolinska Institute

Stockholm, , Sweden

Countries

Sweden

References

Lund J, Gruber A, Lauri B, Duru AD, Blimark C, Swedin A, Hansson M, Forsberg K, Ahlberg L, Carlsson C, Waage A, Gimsing P, Vangsted AJ, Frolund U, Holmberg E, Gahrton G, Alici E, Hardling M, Mellqvist UH, Nahi H. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma. Cancer Med. 2018 Jun;7(6):2256-2268. doi: 10.1002/cam4.1422. Epub 2018 Apr 19.

Reference Type: DERIVED

PMID: 29673108 (View on PubMed)

Other Identifiers

2010-021857-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

PI-RV-MM-10-07/ RV-MM-PI 0627

Identifier Type: -

Identifier Source: org_study_id